RUNX2 and hepatocellular carcinoma: To evaluate whether RUNX2 was highly expressed and correlated with the clinical outcome following anti-PD1 treatment, we used spatial transcriptomics data from 8 anti-PD1-treated HCC patients, including five nonresponders and three responders collected from Mendeley Data (skrx2fz79n) [24].